AhR Agonists for Psoriasis: A Novel Mechanism for Treatment of PsO
Psoriasis is a difficult disease to manage due to a variety of factors including fluctuations in disease severity, limited treatment options, and a limited understanding of the pathogenesis of disease. Recently, the first new topical for PsO since 1997 was approved for adults with plaque PsO. This agent is a novel, steroid-free aryl hydrocarbon receptor (AhR) agonist with no restrictions for duration, location, or extent of use. With the introduction of a first-in-class agent, clinicians must understand the mechanism of action, how it differs from other available topical therapies, and how to prescribe it in clinical practice. Further, because of the treatment benefits, it is important that clinicians are knowledgeable of the clinical efficacy and safety of AhR agonists to improve patient outcomes. Therefore, this educational activity will focus on disease pathogenesis, the novel mechanism of action, and clinical data for AhR agonists in patients with plaque PsO through medical animation and clinical evidence-based discussion.
This activity is designed for an audience of physicians, nurses, pharmacists, and other advanced practice providers (nurse practitioners/physician assistants) in medical practices that specialize in dermatology.
- Discuss the pathogenesis of plaque PsO and how current therapies disrupt mechanisms of disease.
- Assess the mechanism of action, how it differs from other available therapies, and clinical use of AhR agonists.
- Evaluate the clinical efficacy and safety data for AhR agonists in patients with plaque PsO as well as emerging applications.
Linda F. Stein Gold, MD
Director of Clinical Research
Henry Ford Health
April W. Armstrong, MD, MPH
Professor and Chief of Dermatology
University of California Los Angeles
Los Angeles, CA
Leon H. Kircik, MD
Physicians Skin Care, PLLC, Louisville, KY
Skin Sciences, PLLC, Louisville, KY
DermResearch, PLLC, Louisville, KY
Credit provided by AKH Inc., Advancing Knowledge in Healthcare
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio dba LiVDerm. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
1 ANCC contact hour
This activity is supported by an educational grant from Dermavant Sciences, Inc.
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
|April Armstrong, MD||Consultant||Almirall, Arcutis, ASLAN, Beiersdorf, BMS, Dermavant, Lilly, Galderma, Incyte, Janssen, LEO, Modernizing Medicine, Nimbus, Novartis, Ortho Derm, Pfizer, Regeneron, Sanofi, Sun Pharma, UCB|
|Researcher||Abbvie, ASLAN, BMS, Dermavant, Lilly, Galderma, Incyte, Janssen, LEO, Nimbus, Novartis, Ortho Derm, Pfizer, Sanofi, UCB|
|Speaker||Abbvie, BMS, Regeneron, Sanofi, UCB|
|Leon Kircik, MD||Consultant, Speaker||Abbott, Acambis, Aclaris, Allergan, Almirall, Amgen, Anacor, Astellas, Asubio, Berlex, Biogen-Idec, Biolife, Biopelle, Boehringer-Ingleheim, Breckenridge Pharma, Cellceutix, Celgene, Centocor, Cipher, Coherus, Colbar, Collagenex, Combinatrix, Connetics, Coria, Dermavant, Dermik, Dermira, Dow, Dusa Pharmaceuticals, Eli Lilly, Exeltis, EOS, Ferndale, Galderma, Genentech, Glaxo-Smith Kline, HealthPoint, Idera, Intendis, Innovail, Isdin, Johnson & Johnson, 3M, Leo, L'Oreal, Maruho, Medicis, Merck, Merz, NanoBio, Novartis, Novan, Nucryst, Obagi, Onset Therapeutics, OrthoNeutrogena, PediaPharma, Pfizer, PharmaDerm, Promius, Puracap, QLT, Quatrix, Quinnova, Serono, SkinMedica, Stiefel, Sun Pharma, Taro, TolerRx, Triax Pharmaceuticals, UCB, Valeant, Warner & Chilcott, Xenoport, ZAGE|
|Linda Stein Gold, MD||Advisory Board||Galderma, Ortho Derm, Almirall, Sun|
|Consultant, Researcher and Speaker||Galderma, Ortho Derm, Almirall, Sun, Cutera|
Dorothy Caputo, MA, BSN, RN, VP Healthcare CE and Operations
|N/A||Nothing to disclose|
|Michele Bielarski, RN (planner/reviewer)||N/A||Nothing to disclose|
|AKH Inc Staff and Planners||N/A||Nothing to disclose|
|Tarsus dba LiVDerm Staff and Planners||N/A||Nothing to disclose|
|All of the relevant financial relationships listed for these individuals have been mitigated.|
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
If you would like to opt out from future communications from AKH please send an email to firstname.lastname@example.org with your information with "Opt Out" in the subject line.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.